-
- Nitin Jain
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Kathryn G. Roberts
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;
-
- Elias Jabbour
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Keyur Patel
- Department of Hematopathology,
-
- Agda Karina Eterovic
- Institute for Personalized Cancer Therapy, and
-
- Ken Chen
- Institute for Personalized Cancer Therapy, and
-
- Patrick Zweidler-McKay
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Xinyan Lu
- Department of Hematopathology,
-
- Gloria Fawcett
- Institute for Personalized Cancer Therapy, and
-
- Sa A. Wang
- Department of Hematopathology,
-
- Sergej Konoplev
- Department of Hematopathology,
-
- Richard C. Harvey
- Department of Pathology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; and
-
- I-Ming Chen
- Department of Pathology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; and
-
- Debbie Payne-Turner
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;
-
- Marcus Valentine
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;
-
- Deborah Thomas
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Guillermo Garcia-Manero
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Farhad Ravandi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Jorge Cortes
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Steven Kornblau
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Susan O’Brien
- Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA
-
- Sherry Pierce
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Jeffrey Jorgensen
- Department of Hematopathology,
-
- Kenna R. Mills Shaw
- Institute for Personalized Cancer Therapy, and
-
- Cheryl L. Willman
- Department of Pathology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; and
-
- Charles G. Mullighan
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;
-
- Hagop Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Marina Konopleva
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
説明
<jats:title>Key Points</jats:title> <jats:p>Approximately 20% to 25% of adults with B-ALL have Ph-like ALL with increased frequency of Ph-like ALL in adults with Hispanic ethnicity. Adult patients with CRLF2+ ALL have poor long-term outcomes; novel strategies are needed to improve the outcomes.</jats:p>
収録刊行物
-
- Blood
-
Blood 129 (5), 572-581, 2017-02-02
American Society of Hematology
